Compass Group Backs Full-Year View After 3Q Organic Revenue Growth
By Christian Moess Laursen
Compass Group on Tuesday backed its full-year guidance after organic revenue grew in the third quarter of fiscal 2023.
The U.K. catering contractor said organic revenue grew 15% in the quarter ended June 30, a slowing from 25% at the half-year, while year-to-date organic revenue has grown 21%, driven by client retention rate of 96.7%, net new business growth, pricing and volume growth.
The FTSE 100-listed company said it will continue to focus on bolt-on acquisition, and that its net expenditure year-to-date on acquisitions and disposals was 272 million pounds ($348.9 million).
If current currency movements continue for the remainder of the year, Compass expects this to have a positive impact on revenue and operating profit of GBP593 million and GBP43 million, respectively.
Looking ahead, the company reaffirmed its full-year view, and added that long-term it sees mid-to-high single-digit organic growth and a return to its historical margin, leading to profit growth above revenue growth, it said.
Write to Christian Moess Laursen at christian.moess@wsj.com
(END) Dow Jones Newswires
July 25, 2023 02:30 ET (06:30 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Going Into Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening in the Markets This Week
-
4 Top Dividend-Paying REIT Stock Picks
-
After Earnings, Is Netflix Stock a Buy, a Sell, or Fairly Valued?
-
P-CAPE: A Better Way for Investors to Estimate Future Returns
-
Which Stocks Have Driven the Stealth Large-Value Rally?
-
Forecasts for Q2 GDP Report Show a Healthy but Slowing Economy
-
5 Stocks to Buy as the Market Rally Broadens
-
4 Top US Travel Stock Picks
-
How Do Interest Rates Affect Stock Market Returns?
-
American Airlines Earnings: Ticket Distribution Misstep Affected Results
-
Going Into Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
3 Top Cybersecurity Stock Picks for Long-Term Investors
-
AbbVie Earnings: Firm Sees Strong Next-Generation Immunology Drugs Sales
-
Ford Earnings: Warranty Problems on Older Vehicles Slam Results
-
ServiceNow Earnings: Operating on a Higher Plane Within Enterprise Software